CA2442410A1 - Duloxetine for treatment of hot flashes - Google Patents
Duloxetine for treatment of hot flashes Download PDFInfo
- Publication number
- CA2442410A1 CA2442410A1 CA002442410A CA2442410A CA2442410A1 CA 2442410 A1 CA2442410 A1 CA 2442410A1 CA 002442410 A CA002442410 A CA 002442410A CA 2442410 A CA2442410 A CA 2442410A CA 2442410 A1 CA2442410 A1 CA 2442410A1
- Authority
- CA
- Canada
- Prior art keywords
- duloxetine
- hot flashes
- treatment
- raloxifene
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 title claims abstract description 60
- 229960002866 duloxetine Drugs 0.000 title claims abstract description 59
- 208000033830 Hot Flashes Diseases 0.000 title claims abstract description 44
- 206010060800 Hot flush Diseases 0.000 title claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 27
- 238000009164 estrogen replacement therapy Methods 0.000 claims abstract description 13
- 241000124008 Mammalia Species 0.000 claims abstract description 9
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 20
- 229960004622 raloxifene Drugs 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 229960002119 raloxifene hydrochloride Drugs 0.000 claims description 2
- BKXVVCILCIUCLG-UHFFFAOYSA-N raloxifene hydrochloride Chemical group [H+].[Cl-].C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 BKXVVCILCIUCLG-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 241000282412 Homo Species 0.000 claims 2
- 239000000902 placebo Substances 0.000 description 12
- 229940068196 placebo Drugs 0.000 description 12
- 230000000694 effects Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 229960004688 venlafaxine Drugs 0.000 description 5
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 5
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 4
- 229940076279 serotonin Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010027304 Menopausal symptoms Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000009167 androgen deprivation therapy Methods 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001457 vasomotor Effects 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 206010016334 Feeling hot Diseases 0.000 description 1
- 108700012941 GNRH1 Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- ZEUITGRIYCTCEM-UHFFFAOYSA-N duloxetine Chemical group C=1C=CC2=CC=CC=C2C=1OC(CCNC)C1=CC=CS1 ZEUITGRIYCTCEM-UHFFFAOYSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000012055 enteric layer Substances 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000000966 norepinephrine reuptake Effects 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 238000011474 orchiectomy Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27989601P | 2001-03-29 | 2001-03-29 | |
| US60/279,896 | 2001-03-29 | ||
| US34808402P | 2002-01-11 | 2002-01-11 | |
| US60/348,084 | 2002-01-11 | ||
| PCT/US2002/005113 WO2002078691A1 (en) | 2001-03-29 | 2002-03-15 | Duloxetine for treatment of hot flashes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2442410A1 true CA2442410A1 (en) | 2002-10-10 |
Family
ID=26959949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002442410A Abandoned CA2442410A1 (en) | 2001-03-29 | 2002-03-15 | Duloxetine for treatment of hot flashes |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1383495A1 (enExample) |
| JP (1) | JP2004525940A (enExample) |
| CA (1) | CA2442410A1 (enExample) |
| WO (1) | WO2002078691A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050049476A (ko) * | 2002-08-14 | 2005-05-25 | 파마시아 앤드 업존 캄파니 엘엘씨 | 홍조를 치료하기 위한 레복세틴의 용도 |
| US20040152710A1 (en) * | 2002-10-15 | 2004-08-05 | Deecher Darlene Coleman | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| US7419980B2 (en) | 2003-10-14 | 2008-09-02 | Wyeth | Fused-aryl and heteroaryl derivatives and methods of their use |
| US7531543B2 (en) | 2003-10-14 | 2009-05-12 | Wyeth | Phenylpiperazine cycloalkanol derivatives and methods of their use |
| US7550485B2 (en) | 2003-10-14 | 2009-06-23 | Wyeth | Substituted N-heterocycle derivatives and methods of their use |
| US7365076B2 (en) | 2003-10-14 | 2008-04-29 | Wyeth | Substituted aryl cycloalkanol derivatives and methods of their use |
| US7524846B2 (en) | 2003-10-14 | 2009-04-28 | Wyeth | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use |
| US7402698B2 (en) | 2003-10-14 | 2008-07-22 | Wyeth | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use |
| US7491723B2 (en) | 2003-10-14 | 2009-02-17 | Wyeth | Alkanol and cycloalkanol-amine derivatives and methods of their use |
| KR20060121178A (ko) * | 2003-12-12 | 2006-11-28 | 일라이 릴리 앤드 캄파니 | 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제 |
| US7414052B2 (en) | 2004-03-30 | 2008-08-19 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
| US7517899B2 (en) | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
| EP1904039A2 (en) * | 2005-06-20 | 2008-04-02 | Cadila Healthcare Ltd. | Controlled release dosage formulation of duloxetine |
| CN107249615B (zh) * | 2015-04-07 | 2021-02-05 | 株式会社明治 | 潮热抑制剂 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5508276A (en) * | 1994-07-18 | 1996-04-16 | Eli Lilly And Company | Duloxetine enteric pellets |
| CA2250288A1 (en) * | 1996-03-11 | 1997-09-18 | Eli Lilly And Company | Methods of treating or preventing interstitial cystitis |
| AU3306399A (en) * | 1998-03-02 | 1999-09-20 | Eli Lilly And Company | Fluoxetine hydrochloride for decreasing hot flashes |
-
2002
- 2002-03-15 EP EP02707828A patent/EP1383495A1/en not_active Withdrawn
- 2002-03-15 JP JP2002576957A patent/JP2004525940A/ja active Pending
- 2002-03-15 WO PCT/US2002/005113 patent/WO2002078691A1/en not_active Ceased
- 2002-03-15 CA CA002442410A patent/CA2442410A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002078691A1 (en) | 2002-10-10 |
| EP1383495A1 (en) | 2004-01-28 |
| JP2004525940A (ja) | 2004-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2442410A1 (en) | Duloxetine for treatment of hot flashes | |
| JP2001517619A (ja) | 行状異常症の処置 | |
| KR20010024218A (ko) | 반항성 장애의 치료 | |
| EP0123469B1 (en) | Use of fluoxetine for the manufacture of an anti-anxiety agent | |
| JP2002505280A (ja) | 一過性熱感を軽減するための塩酸フルオキセチン | |
| CN108236608A (zh) | 大麻二酚与氨己烯酸的药物组合物及其用途 | |
| WO2024160030A1 (zh) | 一种组合物及其在制备治疗神经性疼痛药物中的应用 | |
| US6683114B2 (en) | Treatment of psoriasis | |
| AU730448B2 (en) | Methods of treating or preventing interstitial cystitis | |
| US20040152733A1 (en) | Duloxetine for treatment of hot flashes | |
| JP2004091473A (ja) | 色素沈着改善治療薬 | |
| US6150396A (en) | Methods of treating or preventing interstitial cystitis | |
| Aminoff | Basic & clinical pharmacology | |
| CN114931567B (zh) | 咖啡酰丁二胺在制备预防或治疗失眠药物中的应用 | |
| CN102283832B (zh) | 一种预防或治疗高血压肥胖患者的药物组合物及用途 | |
| JP2000514441A (ja) | 月経前症候群の１又は複数の症状を抑制するための医薬組成物の製造のための３，４―ジフェニルクロマンの使用 | |
| CN118717783A (zh) | 异夏佛塔苷及其组合物和用途 | |
| US5733937A (en) | Methods for alleviating symptoms of premenstrual syndrome and late luteal phase dysphoric disorder | |
| EP4333812A1 (en) | Alpelisib formulation | |
| CN121041281A (zh) | 一种改善双相抑郁的药物组合物及其药物制剂和应用 | |
| JPWO2022182733A5 (enExample) | ||
| CN101229174B (zh) | 一种含有盐酸依匹斯汀的抗过敏组合物 | |
| CN119325372A (zh) | 间苯三酚制剂和使用方法 | |
| OLTMAN et al. | COMPARISON OF MARPLAN AND TOFRĀNIL IN THE TREATMENT OF DEPRESSIVE STATES | |
| US20110245212A1 (en) | Methods of alleviating the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |